Somavert Related Clinical Trials
Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency [Recruiting]
Acute Application of Pegvisomant and Octreotide in Acromegaly [Completed]
Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects [Completed]
Tissue Biomarker for Pegvisomant Action [Completed]
Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients [Completed]
Acromegaly Combination Treatment Study [Recruiting]
Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients [Completed]
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors [Terminated]
Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant [Recruiting]
Non Interventional Study For Patients Treated With Somavert® [Completed]
Long Term Use of Pegvisomant For A Regulatory Post Marketing Commitment Plan [Active, not recruiting]
Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes [Active, not recruiting]
Canadian Pegvisomant Compassionate Study In Acromegalic Patients [Completed]
Pegvisomant And Sandostatin LAR Combination Study [Completed]
Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients [Completed]
Long Term Study With B2036-PEG [Completed]
Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients [Completed]
Effect of Pegvisomant on GH/IGF-I Relationship in GHD [Terminated]
A Relative Bioavailability Study To Evaluate Safety, Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects [Completed]
A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome [Completed]
A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly [Completed]
Effect of DPP4 Inhibition on Growth Hormone Secretion [Recruiting]
Growth Hormone Signaling in Vivo in Humans [Completed]
Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism? [Recruiting]
The Relationship Between the Growth Hormone (GH)- Insulin Like Growth Factor I (IGF-I) System and the Inflammatory System in Healthy Normal Persons [Enrolling by invitation]
Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During Fasting [Recruiting]
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly [Completed]
Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content [Completed]
Acromegaly Treatment Quality of Life Study [Recruiting]
Cardiac Function and Morphology Evaluated by Magnetic Resonance Imaging in Growth Hormone Deficiency and Acromegaly [Completed]
Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly [Recruiting]
|
